These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36494687)

  • 1. Time-varying parameters of glycemic control and glycation in relation to arterial stiffness in patients with type 1 diabetes.
    Helleputte S; Calders P; Rodenbach A; Marlier J; Verroken C; De Backer T; Lapauw B
    Cardiovasc Diabetol; 2022 Dec; 21(1):277. PubMed ID: 36494687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial stiffness in patients with type 1 diabetes and its comparison to cardiovascular risk evaluation tools.
    Helleputte S; Van Bortel L; Verbeke F; Op 't Roodt J; Calders P; Lapauw B; De Backer T
    Cardiovasc Diabetol; 2022 Jun; 21(1):97. PubMed ID: 35681143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.
    Wannamethee SG; Welsh P; Papacosta O; Ellins EA; Halcox JPJ; Whincup PH; Sattar N
    Atherosclerosis; 2017 Sep; 264():36-43. PubMed ID: 28759844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population?
    Gelžinský J; Mayer O; Seidlerová J; Mateřánková M; Mareš Š; Kordíkova V; Trefil L; Cífková R; Filipovský J
    Hypertens Res; 2021 May; 44(5):518-527. PubMed ID: 33437026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study.
    Birukov A; Cuadrat R; Polemiti E; Eichelmann F; Schulze MB
    Cardiovasc Diabetol; 2021 Jun; 20(1):110. PubMed ID: 34176469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater daily glucose variability and lower time in range assessed with continuous glucose monitoring are associated with greater aortic stiffness: The Maastricht Study.
    Foreman YD; van Doorn WPTM; Schaper NC; van Greevenbroek MMJ; van der Kallen CJH; Henry RMA; Koster A; Eussen SJPM; Wesselius A; Reesink KD; Schram MT; Dagnelie PC; Kroon AA; Brouwers MCGJ; Stehouwer CDA
    Diabetologia; 2021 Aug; 64(8):1880-1892. PubMed ID: 33991193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes.
    Wakasugi S; Mita T; Katakami N; Okada Y; Yoshii H; Osonoi T; Kuribayashi N; Taneda Y; Kojima Y; Gosho M; Shimomura I; Watada H
    Cardiovasc Diabetol; 2021 Jan; 20(1):15. PubMed ID: 33413339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
    Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
    Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HbA1c but not diabetes duration predicts increased arterial stiffness in adolescents with poorly controlled type 1 diabetes.
    Obermannova B; Petruzelkova L; Sulakova T; Sumnik Z
    Pediatr Diabetes; 2017 Jun; 18(4):304-310. PubMed ID: 27075550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness.
    Gelžinský J; Mayer O; Seidlerová J; Mateřánková M; Mareš Š; Kordíková V; Trefil L; Cífková R; Filipovský J
    Hypertens Res; 2020 Feb; 43(2):111-120. PubMed ID: 31636359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. THE ADDED AND INTERPRETATIVE VALUE OF CGM-DERIVED PARAMETERS IN TYPE 1 DIABETES DEPENDS ON THE LEVEL OF GLYCEMIC CONTROL.
    Helleputte S; De Backer T; Calders P; Pauwels B; Shadid S; Lapauw B
    Endocr Pract; 2021 Jan; 27(1):44-50. PubMed ID: 33475500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of arterial stiffness in paediatric patients with type 1 diabetes mellitus.
    Georeli E; Stamati A; Dimitriadou M; Chainoglou A; Tsinopoulou AG; Stabouli S; Christoforidis A
    J Diabetes Complications; 2024 Aug; 38(8):108782. PubMed ID: 38917602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus.
    Farhan SS; Hussain SA
    Diabetes Metab Syndr; 2019; 13(4):2457-2461. PubMed ID: 31405660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study.
    van Eupen MG; Schram MT; van Sloten TT; Scheijen J; Sep SJ; van der Kallen CJ; Dagnelie PC; Koster A; Schaper N; Henry RM; Kroon AA; Smit AJ; Stehouwer CD; Schalkwijk CG
    Hypertension; 2016 Oct; 68(4):956-63. PubMed ID: 27550921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates of aortic stiffness progression in patients with type 2 diabetes: importance of glycemic control: the Rio de Janeiro type 2 diabetes cohort study.
    Ferreira MT; Leite NC; Cardoso CR; Salles GF
    Diabetes Care; 2015 May; 38(5):897-904. PubMed ID: 25678104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis.
    Mac-Way F; Couture V; Utescu MS; Ignace S; De Serres SA; Loignon RC; Marquis K; Larivière R; Agharazii M
    Int Urol Nephrol; 2014 Apr; 46(4):817-24. PubMed ID: 24242737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes.
    Llauradó G; Ceperuelo-Mallafré V; Vilardell C; Simó R; Gil P; Cano A; Vendrell J; González-Clemente JM
    J Endocrinol; 2014 Jun; 221(3):405-13. PubMed ID: 24681829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?
    Mayer O; Gelžinský J; Seidlerová J; Mateřánková M; Mareš Š; Svobodová V; Trefil L; Cífková R; Filipovský J
    J Hum Hypertens; 2021 Mar; 35(3):240-249. PubMed ID: 32203073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High intake of dietary advanced glycation end-products is associated with increased arterial stiffness and inflammation in subjects with type 2 diabetes.
    Di Pino A; Currenti W; Urbano F; Scicali R; Piro S; Purrello F; Rabuazzo AM
    Nutr Metab Cardiovasc Dis; 2017 Nov; 27(11):978-984. PubMed ID: 28958695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arterial stiffness in adolescents and young adults with and without type 1 diabetes: the SEARCH CVD study.
    Shah AS; Wadwa RP; Dabelea D; Hamman RF; D'Agostino R; Marcovina S; Daniels SR; Dolan LM; Fino NF; Urbina EM
    Pediatr Diabetes; 2015 Aug; 16(5):367-74. PubMed ID: 25912292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.